Sunday - May 11, 2025
OKLAHOMA CITY, Oct. 2, 2024 /PRNewswire/ -- Ambetter of Oklahoma, a product offered by a Centene Corporation (NYSE: CNC) company which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, announced today it will reduce plan premiums to residents in 36 counties in Oklahoma for 2025. Open enrollment for the Health Insurance Marketplace for Oklahoma runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Ambetter of Oklahoma is focused on improving our members' experiences by expanding our provider network and bringing down the cost of insurance," said Plan President and CEO of Oklahoma Complete Health Clay Franklin. "By reducing our plan premiums by 8%, we are excited to offer Oklahomans access to affordable and comprehensive coverage."
Ambetter of Oklahoma offers its members access to quality care, convenient services, and valuable rewards. 2025 benefits and offerings include:
Below is the full list of counties in which Ambetter of Oklahoma will be offered:
Oklahoma residents interested in learning more about Ambetter of Oklahoma or enrolling in a health plan during the open enrollment period may visit AmbetterofOklahoma.com.
About Ambetter of Oklahoma
Ambetter of Oklahoma serves under-insured and uninsured populations through the Federal Health Insurance Marketplace. Ambetter of Oklahoma is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Oklahoma. For more information, visit ambetterhealth.com/en/ok/. This is a solicitation for insurance. For information on your right to receive an Ambetter of Oklahoma plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$62.79 |
Daily Change: | 0.37 0.59 |
Daily Volume: | 4,305,694 |
Market Cap: | US$31.700B |
April 25, 2025 February 24, 2025 February 04, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load